Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Epizyme (EPZM) PT Lowered to $19 at RBC Capital; Reiterates Outperform
March 9, 2017 1:20 PM ESTRBC Capital lowered its price target on Epizyme (NASDAQ: EPZM) to $19.00 (from $26.00) while maintaining a Outperform rating. Epizyme provided a development update and discussed its current understanding of tazemetostats mechanism of action .
Analyst Simos Simeonidis commented, "Epizyme provided a development update on... More
Epizyme (EPZM) Tops Q4 EPS by 5c
March 9, 2017 6:36 AM ESTEpizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65).
For earnings history and earnings-related data on Epizyme (EPZM) click here.
... More